Novo Nordisk phases out key insulin products in Germany by 2027

A major shift in diabetes care is coming. Patients must adapt as Novo Nordisk retires long-standing insulin options—but safer, approved alternatives exist.

, and Administrator

2025 November 12 . 7:00 AM

1 min read

There is a pharmacy store and there is a vehicle in front of it and there is a building in the left... — There is a pharmacy store and there is a vehicle in front of it and there is a building in the left corner.

Novo Nordisk phases out key insulin products in Germany by 2027

Novo Nordisk has announced the discontinuation of certain insulin products in Germany. The move, set to occur in phases by the end of 2025 and 2026, includes the prefilled insulin Fiasp PumpCart. However, insulin aspart will remain available in other forms.

The German Federal Institute for Drugs and Medical Devices (BfArM) has confirmed this decision, stating no safety or quality concerns. Affected insulin products include human insulin, insulin detemir, and insulin aspart. Alternatives, approved by the BfArM, range from other once-daily or once-weekly basal insulin products to short- and rapid-acting insulin products like insulin aspart, insulin lispro, and insulin glulisine. Mixed insulin alternatives include other mixed insulin products or basal-bolus therapy, with dose adjustments and close glucose monitoring required during switching.

From 2026, insulin products such as Protaphane FlexPen, Protaphane Penfill, Levemir FlexPen, and Levemir Penfill will no longer be available. In 2027, Actrapid FlexPen, Actrapid Penfill, Actraphane 30 FlexPen, Actraphane 30 Penfill, and Actraphane 50 Penfill will also be discontinued. Patients are advised to monitor their glucose levels closely, especially during the initial switch and for vulnerable groups like pregnant women and children.

While the discontinuation of these insulin products may require patients to adjust their treatment plans, alternative insulin products are available. Close collaboration with healthcare providers and careful monitoring of blood glucose levels will be crucial during this transition.